Revolution Medicines Inc
RVMDHealthcare|Biotechnology|USA
$186.89
-4.33 (-2.26%)
Tangible Book
$7.14
Upcoming Data Readouts (13)
Dec 2026
Est. completion
P1Non-small Cell Lung Cancer (NSCLC)
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06040541n=604
Mar 2027
Est. completion
P1Non-Small Cell Lung Cancer (NSCLC)
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
NCT05462717n=222
May 2027
Est. completion
P1P2Colorectal Cancer
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
NCT06445062n=1,130
May 2027
Est. completion
P1P2Non-small Cell Lung Cancer (NSCLC)
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
NCT05379985n=754
Jun 2027
Est. completion
P1P2Non-Small Cell Lung Cancer, NSCLC
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
NCT06162221n=616
Jun 2027
Est. completion
P1P2PDAC
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
NCT06922591n=183
Dec 2027
Est. completion
P3NSCLC (Non-small Cell Lung Cancer)
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784n=590
Apr 2028
Est. completion
P1Non-small Cell Lung Cancer (NSCLC)
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
NCT07349537n=574
Jun 2028
Est. completion
P3Pancreatic Cancer
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445n=900
Dec 2028
Est. completion
P1P2Non-Small Cell Lung Cancer (NSCLC)
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
NCT06128551n=534
Dec 2028
Est. completion
P3Pancreatic Cancer
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
NCT07621718n=670
May 2029
Est. completion
P1P2Advanced Solid Tumors
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
NCT07397338n=370
May 2029
Est. completion
P3Pancreatic Cancer
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232n=500
Awaiting Results (1)
Trials past primary completion date but still active — data readout may be imminent.
Jun 2026
P3
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
NCT06625320